G1 Therapeutics Inc (NASDAQ:GTHX) has received a consensus rating of “Buy” from the eleven ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $66.00.
GTHX has been the topic of several analyst reports. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a report on Wednesday, March 6th. BidaskClub upgraded G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, February 12th. B. Riley began coverage on G1 Therapeutics in a report on Thursday, February 7th. They issued a “buy” rating and a $55.00 target price on the stock. Zacks Investment Research upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 12th. Finally, JPMorgan Chase & Co. cut G1 Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $59.00 to $41.00 in a report on Wednesday, January 23rd.
GTHX stock traded down $0.04 during trading on Thursday, hitting $15.08. The company had a trading volume of 326,839 shares, compared to its average volume of 299,386. G1 Therapeutics has a one year low of $14.77 and a one year high of $69.57. The stock has a market capitalization of $597.56 million, a PE ratio of -5.89 and a beta of 2.37.
In other G1 Therapeutics news, Director Cynthia Schwalm purchased 1,420 shares of the business’s stock in a transaction on Wednesday, December 26th. The shares were purchased at an average cost of $18.45 per share, for a total transaction of $26,199.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 15.92% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the business. FMR LLC boosted its holdings in shares of G1 Therapeutics by 6.9% during the 4th quarter. FMR LLC now owns 5,577,754 shares of the company’s stock worth $106,814,000 after buying an additional 361,091 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of G1 Therapeutics by 6.9% during the 4th quarter. BlackRock Inc. now owns 1,963,714 shares of the company’s stock worth $37,604,000 after buying an additional 126,892 shares in the last quarter. Vanguard Group Inc boosted its holdings in shares of G1 Therapeutics by 76.3% during the 3rd quarter. Vanguard Group Inc now owns 1,717,733 shares of the company’s stock worth $89,821,000 after buying an additional 743,596 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of G1 Therapeutics by 76.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,717,733 shares of the company’s stock worth $89,821,000 after buying an additional 743,596 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of G1 Therapeutics by 1,497.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,262,991 shares of the company’s stock worth $54,890,000 after buying an additional 1,183,940 shares in the last quarter. Hedge funds and other institutional investors own 75.08% of the company’s stock.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Further Reading: Fundamental Analysis
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.